Profound Medical Corp. (PROF)
| Market Cap | 220.56M +27.4% |
| Revenue (ttm) | 19.09M +61.2% |
| Net Income | -32.74M |
| EPS | -0.98 |
| Shares Out | 36.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 130,923 |
| Open | 6.33 |
| Previous Close | 6.31 |
| Day's Range | 6.01 - 6.44 |
| 52-Week Range | 4.80 - 8.95 |
| Beta | 0.56 |
| Analysts | Strong Buy |
| Price Target | 11.14 (+85.36%) |
| Earnings Date | Nov 5, 2026 |
About PROF
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-t... [Read more]
Financial Performance
In 2025, Profound Medical's revenue was $16.10 million, an increase of 50.73% compared to the previous year's $10.68 million. Losses were -$42.57 million, 53.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PROF stock is "Strong Buy." The 12-month stock price target is $11.14, which is an increase of 85.36% from the latest price.
News
TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMR...
TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iM...
Profound Medical, Telix Pharma Sign Co-Education Deal To Advance PSMA-Informed Prostate Care
(RTTNews) - Friday, Profound Medical Corp. (PROF) and Telix Pharmaceuticals Limited (TLX) announced a co-education agreement to educate physicians and prostate cancer centers on the complementary role...
Profound Medical enters co-education agreement with Telix Pharmaceuticals
Profound Medical (PROF) announced it is entering into a co-education agreement with Telix Pharmaceuticals (TLX). The agreement establishes a framework through which the companies intend to educate uro...
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides...
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
Profound Medical (PROF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc...
Profound Medical (PROF) Surges 17.1% Pre-Market Amid Broader Market Uncertainty
Profound Medical (PROF) Surges 17.1% Pre-Market Amid Broader Market Uncertainty
Profound Medical (PROF) Projects Strong Q3 Revenue Growth, Shares Jump 16%
Profound Medical (PROF) Projects Strong Q3 Revenue Growth, Shares Jump 16%
Profound Medical (PROF) Projects Over 70% Gross Margin in Q3, Signaling Strong Commercial Momentum
Profound Medical (PROF) Projects Over 70% Gross Margin in Q3, Signaling Strong Commercial Momentum
Profound Medical sees Q3 revenue $9.8M-$10M, consensus $9.56M
Sees Q3 gross margin over 70%. “The significant increase in revenue we expect to report this quarter represents a historic milestone for Profound, reflecting the strong commercial momentum building be...
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ...
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding ...
Profound Medical initiated with a Buy at Titan Partners
Titan Partners initiated coverage of Profound Medical (PROF) with a Buy rating and $12 price target The company’s TULSA-PRO facilitates MRI-guided, incision-free prostate ablation and is supported by ...
Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference
TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative i...
Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference
TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative ...
Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President
TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative i...
Profound Medical Further Strengthens Executive Leadership Team with Appointment of Richard Fabian as President
TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative ...
Profound’s Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days’
Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day TORONTO, Aug. 17, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NAS...
Profound's Introduction of New Real-time Interventional MRI Software Paving the Way for Full ‘TULSA Days'
Most recent TDC software provides a potential roadmap for customers to easily achieve up to 6 TULSA Procedures™ per system per day Most recent TDC software provides a potential roadmap for customers t...
Profound Medical CFO Rashed Dewan steps down, Matthew Sobczyk interim CFO
Profound Medical (PROF) announced the promotion of Matthew Sobczyk from Corporate Controller to Interim CFO, effective immediately. Sobczyk, who first joined Profound in 2020, succeeds Rashed Dewan, w...
Profound Medical Announces Management Change
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative i...
Profound Medical (PROF) Q2 2026 Earnings Call Transcript
Record orders and expanding payer coverage mark commercial inflection.
Profound Medical Launches ‘Let’s Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey
A patient-centered initiative focused on education, connection, and support TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a com...
Profound Medical Launches ‘Let's Huddle', a Global Community Supporting Men Throughout Their Prostate Care Journey
A patient-centered initiative focused on education, connection, and support A patient-centered initiative focused on education, connection, and support
Profound Medical Q2 Earnings Call Highlights
Profound Medical NASDAQ: PROF reported second-quarter 2026 revenue of CAD 2.5 million, up 12% from CAD 2.2 million a year earlier, as the company said the reported figure was affected by the timing of...